5VL3 | Immune System | date | Apr 24, 2017 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
title | Cd22 D1-D3 In Complex With Therapeutic Fab Epratuzumab | ||||||||||||||
authors | T.Sicard, J.Ereno-Orbea, J.P.Julien | ||||||||||||||
compound | source | ||||||||||||||
Molecule: B-Cell Receptor Cd22 Chain: Q, R, S, T Synonym: B-Lymphocyte Cell Adhesion Molecule,Bl-Cam,Sialic Binding Ig-Like Lectin 2,Siglec-2,T-Cell Surface Antigen Le Engineered: Yes |
Organism_scientific: Homo Sapiens Organism_common: Human Organism_taxid: 9606 Gene: Cd22, Siglec2 Expression_system: Homo Sapiens Expression_system_common: Human Expression_system_taxid: 9606 | ||||||||||||||
Molecule: Epratuzumab Fab Heavy Chain Chain: A, C, E, H Engineered: Yes |
Organism_scientific: Mus Musculus, Homo Sapiens Organism_common: Mouse, Human Organism_taxid: 10090, 9606 Expression_system: Homo Sapiens Expression_system_common: Human Expression_system_taxid: 9606 | ||||||||||||||
Molecule: Epratuzumab Fab Light Chain Chain: B, D, F, L Engineered: Yes |
Organism_scientific: Mus Musculus, Homo Sapiens Organism_common: Mouse, Human Organism_taxid: 10090, 9606 Expression_system: Homo Sapiens Expression_system_common: Human Expression_system_taxid: 9606 | ||||||||||||||
symmetry | Space Group: P 1 |
| |||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | 3.10 Å | ||||||||||||
ligand | BMA, GOL, MAN, NAG | enzyme |
| ||||||||||||
Primary reference | Molecular basis of human CD22 function and therapeutic targeting., Ereno-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarne A, Rubinstein JL, Julien JP, Nat Commun. 2017 Oct 2;8(1):764. doi: 10.1038/s41467-017-00836-6. PMID:28970495 |
Data retrieval |
View 5VL3 in 3D |
Visual 3D analysis of 5VL3 |
Structure-derived information |
Sequence-derived information |
Other resources with information on 5VL3 |
OCA© by Jaime Prilusky, 1996-2014,2022 Bioinformatics Unit Weizmann Institute of Science |